Review top news and interview highlights from the week ending November 12, 2021.
Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field. This week’s edition includes coverage of the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 10-14, 2021.
IMA203, an autologous, TCR-engineered T cell (TCR-T), PRAME-directed therapy, has shown efficacy across multiple types of solid cancers. The therapy was well-tolerated and all 12 evaluable patients achieved disease control, defined as stable disease or a partial response.
The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s lead programs and future plans. He discussed programs in Fanconi anemia, LAD-1, and Danon disease, as well as the company’s future research and plans.
BNT211, a CLDN6 chimeric antigen receptor (CAR) T-cell candidate, has shown signs of efficacy in solid tumors with a favorable safety profile, both alone and in combination with a CAR-T cell amplifying RNA vaccine (CARVac).
Isaralgagene civaparvovec (ST-920; Sangamo Therapeutics) has shown efficacy in treating Fabry disease, according to new data from the phase 1/2 STAAR clinical study (NCT04046224). The therapy was well-tolerated and above normal α-Gal A activity was maintained for up to a year after treatment.
A2 Biotherapeutics has announced positive preclinical feasibility data on their mesothelin (MSLN) and carcinoembryonic antigen (CEA)-targeted Tmod chimeric antigen receptor (CAR) T-cell therapies, as well as data from their observational BASECAMP-1 study (NCT04981119).